Carcinoma in situ of urinary bladder
Also known as: Carcinoma in Situ of Bladder / Bladder cancer in situ / Carcinoma in situ of the urinary bladder / In situ Bladder Cancer / Carcinoma in situ of the bladder / Carcinoma in situ of bladder NOS / Carcinoma in situ of urinary bladder (disorder) / Malignant neoplasm of bladder stage 0, with cancer in situ / Bladder cancer stage 0, with cancer in situ
Drug | Drug Name | Drug Description |
---|---|---|
DB12768 | BCG vaccine | A vaccine indicated in the prevention of tuberculosis and the treatment of non-invasive urothelial bladder cancer. |
DB10804 | Bacillus calmette-guerin substrain connaught live antigen | Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1... |
DB16648 | Bacillus calmette-guerin substrain russian BCG-I live antigen | An intravesically-administered live BCG vaccine used to treat papillary urothelial cell carcinoma of the bladder. |
DB10343 | Bacillus calmette-guerin substrain tice live antigen | A live attenuated vaccine against Mycobacterium bovis. |
DB00445 | Epirubicin | An anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB00445 | Epirubicin | DNA topoisomerase 2-alpha | target |
DB00445 | Epirubicin | DNA | target |
DB00445 | Epirubicin | Multidrug resistance-associated protein 1 | transporter |
DB00445 | Epirubicin | UDP-glucuronosyltransferase 2B7 | enzyme |
DB00445 | Epirubicin | Cytosolic phospholipase A2 | enzyme |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB00441 | Gemcitabine | 1 | Recruiting | 1 |
DB00724 | Imiquimod | 1 | Recruiting | 1 |
DB15632 | Zalifrelimab | 1 | Recruiting | 1 |
DB11714 | Durvalumab | 2 | Terminated | 1 |
DB00305 | Mitomycin | 3 | Terminated | 1 |